JPWO2023196941A5 - - Google Patents
Info
- Publication number
- JPWO2023196941A5 JPWO2023196941A5 JP2024559398A JP2024559398A JPWO2023196941A5 JP WO2023196941 A5 JPWO2023196941 A5 JP WO2023196941A5 JP 2024559398 A JP2024559398 A JP 2024559398A JP 2024559398 A JP2024559398 A JP 2024559398A JP WO2023196941 A5 JPWO2023196941 A5 JP WO2023196941A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- nucleotide sequence
- human subject
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329081P | 2022-04-08 | 2022-04-08 | |
| US63/329,081 | 2022-04-08 | ||
| US202263401858P | 2022-08-29 | 2022-08-29 | |
| US63/401,858 | 2022-08-29 | ||
| PCT/US2023/065487 WO2023196941A1 (en) | 2022-04-08 | 2023-04-07 | Treatment of a non-alcoholic fatty liver disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025511854A JP2025511854A (ja) | 2025-04-16 |
| JPWO2023196941A5 true JPWO2023196941A5 (https=) | 2026-04-09 |
| JP2025511854A5 JP2025511854A5 (https=) | 2026-04-09 |
Family
ID=86286479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559398A Pending JP2025511854A (ja) | 2022-04-08 | 2023-04-07 | 非アルコール性脂肪肝疾患の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250283089A1 (https=) |
| EP (1) | EP4504337A1 (https=) |
| JP (1) | JP2025511854A (https=) |
| CN (1) | CN119789859A (https=) |
| CA (1) | CA3247602A1 (https=) |
| WO (1) | WO2023196941A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025074157A1 (en) * | 2023-10-06 | 2025-04-10 | Glaxosmithkline Intellectual Property (No.3) Limited | Treatment of a non-alcoholic fatty liver disease |
| WO2025162271A1 (zh) * | 2024-02-03 | 2025-08-07 | 北京福元医药股份有限公司 | 用于抑制HSD17B13表达的siRNA、其缀合物和药物组合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102515329B1 (ko) | 2016-03-07 | 2023-03-29 | 애로우헤드 파마슈티컬스 인코포레이티드 | 치료용 화합물을 위한 표적화 리간드 |
| MX2018009853A (es) | 2016-09-02 | 2018-11-09 | Arrowhead Pharmaceuticals Inc | Ligandos de direccion. |
| MX2020001912A (es) * | 2017-09-14 | 2020-03-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso. |
| MX2021003077A (es) | 2018-09-19 | 2021-05-27 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresion de 17beta-hsd tipo 13 (hsd17b13), composiciones de dichos agentes, y metodos de uso. |
| TW202202153A (zh) * | 2020-03-26 | 2022-01-16 | 美商艾羅海德製藥公司 | 用於抑制ＰＮＰＬＡ３表現之ＲＮＡｉ劑、其醫藥組成物及使用方法 |
-
2023
- 2023-04-07 CN CN202380045597.9A patent/CN119789859A/zh active Pending
- 2023-04-07 JP JP2024559398A patent/JP2025511854A/ja active Pending
- 2023-04-07 CA CA3247602A patent/CA3247602A1/en active Pending
- 2023-04-07 EP EP23721243.6A patent/EP4504337A1/en active Pending
- 2023-04-07 WO PCT/US2023/065487 patent/WO2023196941A1/en not_active Ceased
- 2023-04-07 US US18/854,700 patent/US20250283089A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7674420B2 (ja) | Ｌｄｈａの発現を阻害するための方法及び組成物 | |
| JP6370860B2 (ja) | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 | |
| ES2676146T3 (es) | Composiciones de ARNi de Serpina1 y métodos de uso de las mismas | |
| JP2021518125A5 (https=) | ||
| JPWO2020061177A5 (https=) | ||
| ES2743600T3 (es) | Métodos de tratamiento de los trastornos inflamatorios vasculares | |
| JP2019500345A (ja) | 肝臓病の処置のための組成物および方法 | |
| JP2019504112A5 (https=) | ||
| US20240285668A1 (en) | Formulations for oral delivery of nucleic acids | |
| JP2019500334A (ja) | がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター４（ｍｃｔ４）アンチセンスオリゴヌクレオチド（ａｓｏ）阻害剤 | |
| RU2766356C2 (ru) | Кобитолимод для применения при лечении воспалительного заболевания кишечника | |
| US11795462B2 (en) | Therapy | |
| JP2025511854A (ja) | 非アルコール性脂肪肝疾患の治療 | |
| JPWO2023196941A5 (https=) | ||
| JPWO2021167841A5 (https=) | ||
| Wang et al. | Aptamer-functionalized-nanoflower loading allicin ameliorates obesity through regulating adipose tissue energy expenditure | |
| CN111630169A (zh) | 用于治疗溃疡性结肠炎患者的组合物及其作为药物的用途 | |
| TW202434264A (zh) | 降低一級預防受試者中重大不良心血管事件風險之方法 | |
| JPWO2022221430A5 (https=) | ||
| HK40115827A (zh) | 用於抑制ldha表达的方法和组合物 | |
| JP2024530030A (ja) | 非天然核酸リガンドを有効成分として含む三重陰性乳癌の治療のための薬学的組成物 | |
| HK40026540B (zh) | 用於抑制ldha表达的方法和组合物 | |
| JPWO2023034761A5 (https=) | ||
| JPWO2023282704A5 (https=) |